Data from new VOYAGER PAD reinforce benefit of XARELTO (rivaroxaban) plus aspirin in patients with PAD and various co-morbid conditions

3373

janssenAn analysis showed benefit of XARELTO plus aspirin in reducing thrombotic hospitalisations for peripheral arterial disease (PAD) patients with and without chronic kidney disease (CKD). A separate analysis demonstrated PAD patients who received XARELTO plus aspirin in addition to statin therapy had the lowest risk of the composite of major adverse cardiovascular events (MACE) or major adverse limb events (MALE) compared to all other treatment groups in the study.

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO (rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularisation (LER), a procedure that restores blood flow to the legs.

Data from the two analyses demonstrate the role that the XARELTO vascular dose plays in PAD patients with and without CKD and in PAD patients with and without a history of statin therapy. Results will be featured at the American College of Cardiology’s 71st Annual Scientific Session (ACC) 2022 (Washington D.C., USA, 2–4 April).

One lesser known but serious cardiovascular condition is PAD, a common, chronic circulatory condition that causes blood vessels to narrow, thereby reducing blood flow to the limbs, and most often the legs. It is a disease that often goes undiagnosed and undertreated.

While it usually starts asymptomatically, PAD can progress to severe symptoms and require revascularisation—a surgical procedure that restores blood flow after arteries have been clogged—to avoid amputation.

“At Janssen, we are continuing to invest in clinical research to help evolve the standard of care for people living with serious cardiovascular diseases, like PAD, an area of critical unmet need,” said James F. List, Global Therapeutic Area Head, Cardiovascular, Metabolism, and Retina at Janssen Research & Development. “Our research continues to support the use of the XARELTO vascular dose and is a treatment option physicians should consider for patients with PAD or coronary artery disease.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here